Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. Analyst Price Forecast Suggests 558.90% Upside As of ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

Additionally given a 30-day option to buy up to an extra 975,000 shares at the same price are underwriters. About $49.5 ...

Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...

Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...